OOIR: Observatory of International Research

Papers

(The TQCC of JACC: Cardiooncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Addressing the Overlooked	99
Driven by Impact, Not Impact Factor	97
The Pursuit of “Best” Anticoagulant for Cancer-Associated Thrombosis	97
Full Issue PDF	86
Atrial Fibrillation in Patients With Cancer	86
LAAO in Cardio-Oncology	83
Full Issue PDF	77
Editorial Board	69
Determining Cause-Specific Mortality in Cancer Survivors	68
Editorial Board	67
JACC: CardioOncology	59
Editorial Board	58
Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms	54
Clinical Practice Guidelines in Cardio-Oncology	51
Reply	44
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy	44
Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism	39
Understanding and Reducing the Social and Environmental Determinants of Health Disparities in Cardio-Oncology	38
Adding a Rock to a Hard Place	37
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	36
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	34
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	34
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support	33
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome	33
Cardiac Surveillance in Immune Checkpoint Inhibitor Therapy	33

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	32
Outcomes of Surgery in Cardiac Angiosarcoma	31
Reply	31
ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity	30
Editorial Board/Officers Page	30
Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis	29
Cardio-Oncology and Health Equity	29
Full Issue PDF	28
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	27
Full Issue PDF	27
Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy	25
How to Treat Diffuse Large B-Cell Lymphoma	24
Premature Cardiac Senescence	24
Full Issue PDF	23
Could Clonal Hematopoiesis Explain the Link Between Increased Cancer Mortality Incidence in Heart Failure?	22
Chest Pain in Cancer Patients	22
Leveraging Population Genomics to Enhance Preventive Cardio-Oncology	22
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities	21
The Cause of Death in Patients With Cancer	21
How to Treat Breast Cancer After Childhood Cancer	21
Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies	20
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	20
Embracing the Power of the Polysocial Risk Score	20
Cardiac Magnetic Resonance in Cardio-Oncology	20
Atherosclerotic Cardiovascular Diseases Are Associated With Incident Metastatic and Nonmetastatic Cancer	19
Inclusion of Exercise in Cancer Treatment Planning	19
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	19
The Rise and Fall of C-Reactive Protein	18
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	18
Cardiovascular Considerations During Cancer Therapy	17
Hormonal Therapy and Cardiovascular Health	17
(Less) Time and Energy	16
Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan	16
Reply	16
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	16
Is Preventative Oophorectomy Safe?	16
Intracardiac Ultrasound and Mapping Integration-Guided Endomyocardial Biopsy for the Diagnosis of Myocardial Melanoma Metastasis	15
Probing the Anthracycline-Induced Myocardial Injury	15
Cardiac Tumors and Innovations in Local Therapies	14
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	14
Management of Amyloid Cardiomyopathy in Resource-Constrained Settings	13
Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes	13
FATAL TRIAD OF IMMUNE CHECKPOINT INHIBITOR THERAPY	13
Endothelin Receptor Blocker Reverses Breast Cancer–Induced Cardiac Remodeling	13
Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability	13
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	13
How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer	13
Cardiovascular Risk Factors Are Associated With Future Cancer	12
Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients	12
Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors	11

The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer	11
Physician Knowledge and Awareness About Cardiac Amyloidosis in the Middle East and Gulf Region	11
Time-Restricted Eating to Reduce Cardiovascular Risk Among Older Breast Cancer Survivors	11
Role of Physical Activity and Cardiac Rehabilitation in Patients Undergoing Hematopoietic Stem Cell Transplantation	11
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	11
Arterial Thromboembolism in Cancer Patients	11
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk	11
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	11
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	10
Epigenomics of Cardio-Oncology	10
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity	10
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	10
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	10
Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors	9
Guiding Treatment With Recovered CTRCD	9
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	9
Preventing Cancer Therapy–Related Cardiotoxicity	9
Priorities in Cardio-Oncology	9
Cardiovascular Safety in Oncology Clinical Trials	9
Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma	8
Reply	8
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	8
Management of Immune Checkpoint Inhibitor–Induced Myocarditis	8
Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy	8
Raise the Flag	8
Cardiotoxicity of BRAF/MEK Inhibitors	8
Editorial Board	8
Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction in Long-Term Survivors of Childhood Cancer	8
When Clot Is Tumor	8
Extensive Cardiac Function Analyses Using Contemporary Echocardiography in Childhood Cancer Survivors	7
Cardiac Risk Stratification Before Lung Cancer Radiation	7
Reply	7
Can We Estimate Cardiorespiratory Fitness in Breast Cancer Survivors Without Exercise?	7
Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies	7
Full Issue PDF	7
How to Manage Atrial Fibrillation Secondary to Ibrutinib	7
Full Issue PDF	7
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	7
Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings	6
How Common Is Pre-Existing Cardiovascular Disease in Cancer Patients	6
Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients	6
Optimal Detection of Cardiac Sequelae	6
How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia	6
The ESC Cardio-Oncology Guidelines	6
The Impact of the Cancer Moonshot on Cardio-Oncology Science	6
Cardiovascular Toxicity During Advanced Prostate Cancer Treatment	6
Cardio-Oncology in Iran	6
Overcoming LGBTQI+ Disparities in Cardio-Oncology	6
Full Issue PDF	6
Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation	6
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer	6
Thank You to Our Community and to Our Peer Reviewers	6
Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy	6
The ESC 2022 Cardio-Oncology Guidelines and the Road Ahead in Cardio-Oncology	6
Full Issue PDF	5
Prostate Cancer and Cardiovascular Risk Factors	5
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	5
Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors	5
Amyloid Cardiomyopathy	5
Screening for Coronary Artery Disease in Cancer Survivors	5
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure	5
My Hope for Cardio-Oncology	5
Full Issue PDF	5
ATTR Cardiomyopathy Meets Multiple Myeloma	5
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	5
Electrophysiological Manifestations of Cardiac Amyloidosis	5
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	5
Ventricular Arrhythmias Due to Glomangiosarcoma Cardiac Metastases	5
Editorial Board	5
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies	5
Uncontrolled Cardiovascular Risk Factors in Prostate Cancer Patients	5
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	5
Transcatheter Compared With Surgical Aortic Valve Replacement in Patients With Previous Chest-Directed Radiation Therapy	5